PCSK9 and Stroke: If, speculatively, CVD and stroke incidence could be halved by PCSK9 therapy [11, 14, 16], direct annual savings would be estimated to be $160 billion, and indirect annual savings might be $85 billion [21], altogether $245 billion savings, in the middle of the range of estimated PCSK9 inhibitor costs of $185–342 billion [17].